CSF3 and vasculitis: Additionally, in patients with a prior history of G-CSF-induced vasculitis or those at elevated risk of inflammatory complications, the use of shorter-acting G-CSF preparations (e.g. filgrastim) may be considered as a potentially safer alternative, given their lower reported association with aortitis compared to long-acting agents such as pegfilgrastim [5].